Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Overview
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Companies Involved in Therapeutics Development
Accendatech Co Ltd
Advanced Vision Technologies (New York)
Astellas Pharma Inc
Beam Therapeutics Inc
Jazz Pharmaceuticals Plc
MDI Therapeutics Inc
Second Genome Inc
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Drug Profiles
ACT-001 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha-1 Antitrypsin Deficiency – Drug Profile
Product Description
Mechanism Of Action
History of Events
AS-3288802 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Bi-specific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke – Drug Profile
Product Description
Mechanism Of Action
defibrotide sodium – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Inhibit SERPINE1 for Open-Angle Glaucoma – Drug Profile
Product Description
Mechanism Of Action
History of Events
MDI-2268 – Drug Profile
Product Description
Mechanism Of Action
History of Events
MDI-2517 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmory Thromboembolism – Drug Profile
Product Description
Mechanism Of Action
SG-500455 – Drug Profile
Product Description
Mechanism Of Action
History of Events
SK-216 – Drug Profile
Product Description
Mechanism Of Action
History of Events
TM-5275 – Drug Profile
Product Description
Mechanism Of Action
History of Events
TM-5441 – Drug Profile
Product Description
Mechanism Of Action
History of Events
TM-5484 – Drug Profile
Product Description
Mechanism Of Action
History of Events
TM-5614 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Dormant Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Discontinued Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) – Product Development Milestones
Featured News & Press Releases
May 24, 2022: Second Genome presents new data at Digestive Disease Week (DDW) 2022 demonstrating that SG-5-00455, a potential first-in-class precision therapeutic, improves epithelial barrier function and promotes mucosal healing in inflammatory bowel disease
Feb 24, 2022: Second Genome virtual KOL event highlighted critical role of mucosal healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
Feb 18, 2022: Second genome presents new preclinical data for SG-5-00455, potential first-in-class development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease (IBD), at the 17th Congress of European Crohn’s and Colitis Organization (ECCO)
Feb 14, 2022: Second Genome to host virtual KOL event to discuss the role of mucosal healing and PAI-1/2 in inflammatory bowel disease on February 23
Feb 10, 2022: Second Genome nomites development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease (IBD)
Dec 02, 2021: ACT001 combined with PD-1 in the treatment of relapsed GBM completed the first subject dosing in the United States at MD Anderson
Nov 18, 2021: Second Genome presents preclinical data at Crohn’s & Colitis Foundation’s IBD Innovate Conference for potential first in class mucosal healing therapeutic SG-5-00455
Nov 08, 2021: Chi’s origil drug achieves "zero" breakthrough and is the first to be granted the rare disease qualification for children by the US FDA
Jul 07, 2021: The new immunomodulator ACT001 shows great potential
May 20, 2021: Jazz to present new data on Defitelio at EHA2021
Nov 13, 2020: Beam Therapeutics presents first data highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at AASLD
Jul 31, 2020: Clinigen receives regulatory approval for Defitelio (Defibrotide) in Australia
May 14, 2020: Jazz Pharmaceuticals announces presentation on Defitelio at Virtual EHA 2020 Meeting
Apr 29, 2020: Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating Defibrotide for the prevention of Veno-Occlusive Disease
Apr 28, 2020: Beam Therapeutics to present first data highlighting base editing program for alpha-1 antitrypsin deficiency at 23rd ASGCT Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Accendatech Co Ltd, 2022
Pipeline by Advanced Vision Technologies (New York), 2022
Pipeline by Astellas Pharma Inc, 2022
Pipeline by Beam Therapeutics Inc, 2022
Pipeline by Jazz Pharmaceuticals Plc, 2022
Pipeline by MDI Therapeutics Inc, 2022
Pipeline by Second Genome Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022